Answers are grounded in this paper and cite their sources.
The use of antipsychotics has been associated with memory deficits as well as a worsening of cognitive symptoms in patients. Dopaminergic receptors have been implicated in these symptoms; however, the role of D 3 receptor activation remains uninvestigated. This study evaluated the effects of haloperidol and/or pramipexole on the novel object recognition (NOR) test in rats and possible alterations in locomotor activity, enzymes related to the dopaminergic system, or its modulators. Male Wistar rats received haloperidol (28 mg/kg, intramuscularly, single administration) and/or pramipexole (0.2 and 1 mg/kg, intraperitoneally, once a day for 28 days). In the NOR test, haloperidol, either alone or co-treated with pramipexole, reduced the time spent exploring both familiar and novel objects, while the NOR index did not differ significantly among the experimental groups. The number of crossings and rearing in the open field test was reduced in animals treated with haloperidol alone and haloperidol combined with pramipexole; however, pramipexole alone did not affect locomotor activity. A higher NOR index was not associated with changes in the number of rearing or crossings. No significant differences were found among the experimental groups on MAO-A, MAO-B, acetylcholinesterase, or catalase activity, TH immunoreactivity, or oxidative stress markers in the hippocampus. Significant correlations between GAD 67 immunoreactivity and the NOR index or time spent in the familiar object were found in the haloperidol-treated group. In conclusion, the haloperidol-induced changes observed in the NOR and open-field tests were not consistently modified by pramipexole, a D 3 receptor agonist.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: